Clinical Trials Logo

Clinical Trial Summary

Pregnancy is associated with significant changes in several aspects of haemostasis, especially an imbalance between procoagulant and anticoagulant factors. These changes contribute to creating a state of hypercoagulability, mainly at the end of pregnancy and during the post-partum period, protecting pregnant women from delivery haemorrhage, but exposing them to a major thromboembolic risk. Vascular diseases of pregnancy (VDP) are obstetric diseases which are linked to an ischaemic origin associated with placental thrombosis. These include pre-eclampsia, retroplacental haematoma, intrauterine growth retardation and even foetal death in utero. A number of risk factors have been identified for these VDPs, some of which have extremely serious consequences, the main one being antiphospholipid syndrome (APS). The diagnosis of VDP in a current or previous pregnancy requires close monitoring and joint management by an obstetrician, haemostasis physician, internist and medical biologist, particularly in terms of pre, peri- and post-partum anticoagulation in patients at increased risk of thromboembolism. The aim of treating APS during pregnancy is : to reduce the occurrence of maternal arterial or venous thrombotic complications in one hand and in the other hand to reduce the occurrence of obstetric complications, which are responsible of a significant morbimortality rate. The detection of a possible APS during pregnancy will therefore determine the specific management of patients. The latest guidelines from the Groupe Français d'Etude sur l'Hémostase et la Thrombose (GFHT) in 2022 recommended a diluted Russell's viper venom time (dRVVT) and an activated partial thromboplastin time (APTT) measured using a sensitive reagent such as silica (SCT) should be used to assess the presence of LA.


Clinical Trial Description

Please remove all personal pronouns. For example, please change "we" to "the investigators" and "you" to "participants." The "Control + Find" function (Ctrl+F) can be used to locate personal pronouns throughout the record. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06133621
Study type Observational
Source Hospices Civils de Lyon
Contact Céline DR BAZIN, DR-
Phone 04 72 35 72 47
Email celine.bazin01@chu-lyon.fr
Status Recruiting
Phase
Start date March 28, 2024
Completion date September 28, 2024

See also
  Status Clinical Trial Phase
Completed NCT00341263 - Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies
Completed NCT01907620 - Circulating Oxidative Stress and Gestational Hypertension. Study of the Evolution of Free-radical Markers of Oxidative Stress From Before to After Childbirth in Two Groups of Women: Normal Pregnancy and Pre-eclampsia. N/A
Completed NCT03692923 - VIRTUAL COMMUNITY for PREGNANT WOMEN N/A
Recruiting NCT04400084 - Using Cotyledon Perfusion to Study Drugs Transfer Across the Placenta
Completed NCT04215484 - Placenta Accreta New Detection Procedure by Rapid Assessment of Serum BNP
Completed NCT00437996 - Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial Phase 3